Skip to main content
Top
Literature
2.
go back to reference Robak E, Robak T (2007) Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma 485:855–865CrossRef Robak E, Robak T (2007) Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma 485:855–865CrossRef
3.
go back to reference Giles FJ, O’Brien SM, Keating MJ (1998) Chronic lymphocytic leukemia in (Richter’s) transformation. Semin Oncol 25:117–125PubMed Giles FJ, O’Brien SM, Keating MJ (1998) Chronic lymphocytic leukemia in (Richter’s) transformation. Semin Oncol 25:117–125PubMed
4.
go back to reference Cerroni L, Zenahlik P, Hofler G (1996) Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia: a clinicopathologic and prognostic study of 42 patients. Am J Surg Pathol 20:1000–1010CrossRefPubMed Cerroni L, Zenahlik P, Hofler G (1996) Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia: a clinicopathologic and prognostic study of 42 patients. Am J Surg Pathol 20:1000–1010CrossRefPubMed
5.
go back to reference Colburn DE, Welch MA, Giles FJ (2002) Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis. Hematology 7:187–188CrossRefPubMed Colburn DE, Welch MA, Giles FJ (2002) Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis. Hematology 7:187–188CrossRefPubMed
Metadata
Title
Leukemia Cutis: A Rare Initial Presentation of Chronic Lymphocytic Leukemia
Authors
Abhenil Mittal
Ajay Gogia
Saumyaranjan Mallick
Ritu Gupta
Publication date
01-04-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-1057-3

Other articles of this Issue 2/2019

Indian Journal of Hematology and Blood Transfusion 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine